A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
Status:
COMPLETED
Trial end date:
2024-12-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of AMG 133 after multiple subcutaneous (SC) administrations in participants with overweight or obesity using various dose regimens.